28 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 28 of 28 clinical reviews.
A complete clinical guide to alcoholic liver disease, MASLD (formerly NAFLD), MASH (formerly NASH), hepatic steatosis, and cirrhosis, including diagnosis, staging, and evidence-based treatment options.
GLP-1 receptor agonists, especially semaglutide, show strong clinical evidence for resolving MASH and reducing liver fibrosis. Learn which drugs are approved, what doses work, and who qualifies.
A clinical deep-dive into whether metabolic-associated steatotic liver disease can fully reverse through diet alone, covering caloric targets, macronutrient strategies, coffee, GLP-1 drugs, and non-invasive fibrosis testing.
MASLD (formerly NAFLD) is now the leading driver of cirrhosis worldwide. Learn how hepatic steatosis progresses to MASH and irreversible fibrosis, what the evidence says about reversal, and which therapies are FDA-approved or in late-stage trials.
A detailed breakdown of resmetirom (Rezdiffra) costs in 2026, including list price, insurance coverage, patient assistance programs, and how to reduce out-of-pocket spending for MASLD/MASH treatment.
How cryptogenic cirrhosis is diagnosed, when burned-out MASH is plausible, and how cancer surveillance, portal hypertension, nutrition, and transplant care are managed.
Coffee may reduce liver fibrosis risk by up to 40%. This clinician-reviewed guide covers the NAFLD-to-MASLD rename, diet reversal, GLP-1 therapy, and non-invasive fibrosis testing.
A clinician-reviewed deep dive into whether fructose uniquely drives metabolic dysfunction-associated steatotic liver disease, how it compares to other dietary fats and sugars, and what the evidence says about diet, GLP-1s, and reversal.
Drug-induced liver injury (DILI) is the leading cause of acute liver failure in the US. Learn which drugs carry the highest risk, how DILI relates to MASLD/MASH, and the clinical steps to protect your liver.
Hepatic steatosis (fatty liver) affects roughly 30% of adults worldwide. Learn about MASLD (formerly NAFLD), progression to MASH and cirrhosis, diagnostic tools, and FDA-approved treatments including resmetirom.
A clinician-reviewed guide to non-invasive liver fibrosis testing: FIB-4, elastography, MRI-PDFF, and the latest GLP-1 trial data for MASLD and MASH.
Lean MASLD affects people with a normal BMI but still causes significant liver damage. Learn who is at risk, how it differs from obesity-related MASLD, and what treatment options exist.
A detailed clinical comparison of liver biopsy, FibroScan (vibration-controlled transient elastography), and MR elastography for staging MASLD/MASH fibrosis, including when each test is appropriate, accuracy data, and treatment implications.
A clinician-reviewed guide to metabolic dysfunction-associated steatotic liver disease (MASLD): how it develops, how it is staged, and which lifestyle changes and medications can reverse it.
MASH, formerly called NASH, is the inflammatory form of metabolic fatty liver disease. Learn how it differs from simple steatosis, how it progresses to cirrhosis, and what FDA-approved and emerging therapies now exist.
MASLD replaced NAFLD in 2023. Learn what changed, how MASH (formerly NASH) is staged, which FDA-approved treatments now exist, and what your liver enzymes actually mean.
People with type 2 diabetes face a 50 to 70% prevalence of MASLD and faster fibrosis progression. Learn the mechanisms, screening tools, and evidence-based treatments your care team should be using.
MASLD (metabolic dysfunction-associated steatotic liver disease) affects up to 75% of people with obesity. Learn the mechanisms, risk factors by subgroup, and evidence-based treatments including GLP-1 agonists and lifestyle changes.
Postmenopausal women face a sharp rise in MASLD risk after estrogen loss. Learn how menopause, diabetes, obesity, and lean MASLD interact, plus current treatment options backed by clinical evidence.
Obeticholic acid causes pruritus in up to 70% of patients. Learn the mechanism, severity grading, management strategies, and how it compares to resmetirom and pioglitazone side effects in MASLD treatment.
Pioglitazone improves liver histology in MASLD/NASH but carries a real fluid-retention and heart failure risk. This clinical guide covers the evidence, who should avoid it, how to monitor safely, and how it compares to resmetirom and obeticholic acid.
Evidence-based resmetirom (Rezdiffra) dosing protocol for metabolic dysfunction-associated steatohepatitis (MASH), including weight-based dosing, titration, monitoring, and comparison with vitamin E therapy.
A full clinical breakdown of resmetirom (Rezdiffyne) side effects, including nausea rates from MAESTRO-NASH, comparisons with obeticholic acid pruritus and pioglitazone heart failure risk, and management strategies for patients with MASLD/MASH.
A clinician-reviewed guide to saroglitazar (Lipaglyn) for metabolic-associated steatotic liver disease, covering mechanism, clinical trial data, dosing, side effects, and how it stacks up against resmetirom (Rezdiffra), pioglitazone, obeticholic acid, and vitamin E.
A clinician-reviewed guide to SGLT2 inhibitors for MASLD, MASH, and liver fibrosis, comparing empagliflozin, dapagliflozin, and canagliflozin against pioglitazone, vitamin E, obeticholic acid, and resmetirom.
A clinician-reviewed guide to vitamin E dosing in NASH (now called MASLD/MASH), covering the PIVENS trial dose, who qualifies, risks of high-dose tocopherol, and where resmetirom fits in the 2024 treatment landscape.
A clinical comparison of vitamin E 800 IU/day vs pioglitazone 30 to 45 mg/day for metabolic dysfunction-associated steatohepatitis (MASH), including the PIVENS trial data, safety profiles, fibroscan vs MRE monitoring, and how resmetirom and GLP-1 agonists fit into the 2024 treatment landscape.
NAFLD and MASLD describe the same fatty liver spectrum but use different diagnostic criteria. Learn what changed, why it matters for diagnosis and treatment, and which interventions, diet, GLP-1s, and more, have the strongest evidence.